Achieving prolonged control of human immunodeficiency virus (HIV)-1 replication after antiretroviral therapy (ART) interruption is one of the aims of present research efforts towards eradication, to alleviate HIV-1 burden, drug toxicity, and costs. Initiation of ART during primary HIV-1 infection (PHI) is associated with reduced size and diversity of viral reservoirs and enhanced immune preservation, relative to chronic infection. This is reflected in prolonged aviremia in a minority of early treated seroconverters who discontinue ART \[[@OFV144C1]--[@OFV144C3]\]. Elucidating the underlying mechanisms may facilitate the development of curative therapy. In this study, we describe the favorable outcome of a woman who initiated ART during a severe acute retroviral syndrome. She stopped therapy 6 years later and has since experienced a decade of apparent spontaneous control. We report the virological and immunological features of this unusual case.

METHODS {#s2}
=======

Quantification of the Human Immunodeficiency Virus-1 Reservoir {#s2a}
--------------------------------------------------------------

Written permission was obtained from the patient for reporting of her case. The patient was infected with a clade C virus. During 17 years of follow-up, HIV-1 viremia was quantified with several validated assays, which included non-B primers in accordance with laboratory and clinical practice at the time. Low copy viremia was determined as described in [Supplementary Methods](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1). Quantification of cell-associated HIV-1 DNA in blood sampled during 2007--2013 was performed as described previously \[[@OFV144C4], [@OFV144C5]\]. Integrated HIV-1 DNA was determined in samples from 2013 onwards by Alu-HIV polymerase chain reaction (PCR), in addition to quantification of total and episomal 2-long terminal repeat (LTR) circles \[[@OFV144C6], [@OFV144C7]\] ([Supplementary Methods](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)).

Human Leukocyte Antigen Typing {#s2b}
------------------------------

The patient\'s human leukocyte antigen (HLA) type was determined by ARMS-PCR using sequence-specific primers as follows: HLA A\*0101, \*3001, B\*4901, Cw\*0701, DRB1 \*0804, DQB1 \*0301 (homozygous at HLA-B, Cw, DR, and DQ loci).

Assessment of Human Immunodeficiency Virus-1-Specific Cellular Immune Responses {#s2c}
-------------------------------------------------------------------------------

T-cell responses to the entire HIV-1 proteome were assessed initially using pools of clade B 15-mer peptides overlapping by 11 amino acids and, subsequently, corresponding overlapping clade C 18-mers, (NIH AIDS Reagent Program, final concentration 2 µg/mL) in ex vivo interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays, as described previously \[[@OFV144C8]\]. Further details are given in [Supplementary Methods](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1). Unfractionated and CD8^+^-depleted peripheral blood mononuclear cells (PBMCs) were also tested in IFN-γ ELISPOT assays with pools of peptides representing "beneficial regions" that are preferentially targeted by individuals with reduced viral loads \[[@OFV144C9]\] ([Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)).

Ex vivo CD8^+^ T-cell viral inhibitory activity was determined using a viral inhibition assay as described previously \[[@OFV144C8]\]. Primary CD4^+^ T cells were superinfected with laboratory-adapted or primary virus isolates (Programme EVA Centre for AIDS Reagents, National Institute for Biological Standards and Control) at a multiplicity of infection of 0.01: HIV-1BaL (CCR5-tropic, clade B), HIV-1IIIB (CXCR4-tropic, clade B), and HIV-1C (CCR5-tropic, clade C).

RESULTS {#s3}
=======

Case Report {#s3a}
-----------

A 23-year-old woman of Ethiopian origin presented in 1997 with a 3-week history of fever, sore throat, rash, lymphadenopathy, myalgia, and arthralgia. Her HIV-1 antibody test was positive with incomplete reactivity on HIV Western blot. She had tested HIV-1 seronegative in 1996. Three consecutive CD4^+^ T-cell counts were \<200 cells/mm^3^, and her viral load was initially \>750 000 HIV-1 copies (c)/mL. The patient started zidovudine 250 mg twice daily, lamivudine 150 mg twice daily, and indinavir 800 mg 3 times a day. The latter was subsequently switched to ritonavir 600 mg twice daily because of intolerance. She remained viremic (up to 94 400 HIV-1 c/mL) while on treatment and required intensification (twice daily saquinavir 400 mg and ritonavir 400 mg), which was initiated in May 1998. Suppression of viremia \<50 HIV-1 c/mL was not achieved until approximately 1 year later, but it was sustained for nearly 5 years thereafter, at which point ART was stopped at the patient\'s request. The pre-ART discontinuation CD4^+^ T-cell count was 863 cells/mm^3^ (30%), with a CD4^+^/CD8^+^ T-cell ratio of 0.7. The patient has since remained asymptomatic with undetectable viremia, normal CD4^+^ T-cell counts, and a CD4^+^/CD8^+^ T-cell ratio \>1 during 10 years of follow-up off ART (Figure [1](#OFV144F1){ref-type="fig"}). A comprehensive screen for antiviral agents by therapeutic drug monitoring on a blood sample from 2008 was negative (Delphic Laboratories Ltd, Merseybio Liverpool, UK). Furthermore, the frequency of activated (CD38^+^) CD8^+^ T cells, which was measured during 2004--2010, remained within normal limits (3%--21%) (Figure [1](#OFV144F1){ref-type="fig"}B). Human leukocyte antigen typing revealed that the patient did not express any HLA class I alleles associated with long-term control of HIV. Figure 1.CD4 cell count and plasma viral load changes (A), CD4/CD8 cell ratios, and percentage of activated (CD38^+^) CD8 T cells (B) during primary infection, antiretroviral therapy, and posttreatment discontinuation are shown. Antiretroviral therapy regimen: nucleoside reverse-transcriptase inhibitors zidovudine/lamivudine days 12--2121 and tenofovir/lamuvidine days 2122--2289; protease inhibitors indinavir days 12--22, ritonavir (full dose) days 23--203, and ritonavir/saquinivir days 204--2289. The assays used to quantify human immunodeficiency virus (HIV)-1 RNA were as follows, in chronological order: Roche Amplicor HIV-1 Monitor version 1.0 assay with non-clade B primers added (first 2 samples in 1997); Roche COBAS Amplicor HIV-1 Monitor, replaced by version 1.5 (Ultrasensitive assay) in October 2004; Abbott LCx HIV-1 assay (January 2005--May 2005); Abbott Real-Time HIV-1 assay (May 2005 onwards). Antiretroviral agents included in therapeutic drug monitoring in 2008 were as follows: lamivudine, efavirenz, atazanavir, amprenavir, indinavir, nelfinavir, lopinavir, ritonavir, saquinavir, darunavir, tipranavir. (C) Susceptibility of the patient\'s CD4^+^ T cells to superinfection with clade (B) and (C) virus isolates and to induction of endogenous HIV-1: frequencies of p24 Ag^+^ CD4^+^ T cells after in vitro activation of CD8-depleted peripheral blood mononuclear cells (PBMCs), followed by superinfection and culture for 6 days, or culture without superinfection (autologous virus) for up to 11 days. (D) Inhibition of replication of superinfecting or autologous viruses by patient\'s CD8^+^ T cells after 6 days\' coculture at CD8/CD4 cell ratios indicated. (E) Responses to individual clade C consensus Gag peptides identified in the peptide matrix assays were confirmed by interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays with unfractionated PBMCs. Negative control values have been subtracted. Some of these peptides overlapped "beneficial" regions within clade B and C Gag that were previously associated with virological control---shown in bold \[[@OFV144C9]\]. (F) CD4^+^ T-cell responses to peptides representing beneficial regions within clade B/C Gag (listed in [Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)) were determined in IFN-γ ELISPOT assays with CD8-depleted PBMCs.

Evidence of a Detectable Human Immunodeficiency Virus-1 Reservoir During Posttreatment Control {#s3b}
----------------------------------------------------------------------------------------------

During the posttreatment period with aviremia, HIV-1 DNA was detected on 4 occasions: 2004 (not quantified), 2007, 2013, and 2014. Total HIV-1 DNA was 285, 619, and 149 copies/10^6^ PBMCs in 2007, 2013, and 2014, respectively. At 15 years of aviremia (2014), integrated HIV-1 DNA and 2-LTR circles were 134.3 (95% confidence interval \[CI\], 56.5--304.4) and 3.9 (95% CI, 0--9.15) copies/10^6^ PBMCs, respectively (Figure [1](#OFV144F1){ref-type="fig"}A). Viremia was undetectable by an ultrasensitive assay (\<2 HIV-1 copies/mL).

CD8^+^ T Cells Sampled After 10 Years of Posttreatment Control Suppress Human Immunodeficiency Virus-1 Replication In Vitro {#s3c}
---------------------------------------------------------------------------------------------------------------------------

Ex vivo CD8^+^ T cells were tested for their capacity to inhibit the replication of clade B and C HIV-1 isolates and of endogenous HIV-1 in autologous CD4^+^ T cells in vitro. At a CD8^+^/CD4^+^ ratio of 1:1, CD8^+^ T cells demonstrated moderate antiviral activity against clade-matched (C, 73.5%) and mismatched (IIIB, 73.3%; BaL, 49%) virus isolates (Figure [1](#OFV144F1){ref-type="fig"}C and D). Efficient suppression of the clade C isolate was also observed at a lower CD8^+^/CD4^+^ T-cell ratio (1:10%--59% vs 30% for IIIB and 22% for BaL). Antiviral activity against the patient\'s endogenous virus was equivalent to HIV-1C at both CD8^+^/CD4^+^ T cell ratios (70.5% and 52.3% for 1:1 and 1:10 ratios, respectively) (Figure [1](#OFV144F1){ref-type="fig"}C and D).

Broad CD4^+^ T-Cell Responses Target Vulnerable Regions Within Gag {#s3d}
------------------------------------------------------------------

Interferon-γ-secreting CD8^+^ and CD4^+^ T cells were predominantly targeted to 14 regions within HIV-1 Gag, Pol, and Nef (Figure [1](#OFV144F1){ref-type="fig"}E, [Supplementary Figure 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)A--C). T-cell responses were also targeted to 7 vulnerable (beneficial) regions within the clade B and C viral proteomes ([Supplementary Table 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)) and were predominantly CD4^+^ T cell-mediated (Figure [1](#OFV144F1){ref-type="fig"}E and 1F, [Supplementary Figure 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)D).

DISCUSSION {#s4}
==========

This case shows that long-term control of viremia and normalization of immune parameters may follow discontinuation of prolonged ART initiated at PHI, even in the context of persistent viremia of nearly 5 log~10~ HIV-1 c/mL during initial ART and the absence of favorable HLA alleles. Such features would typically preclude long-term nonprogressor status \[[@OFV144C10]\].

Salgado et al and Sáez-Cirión et al have reported post-ART virological control after treatment during PHI, despite initial viremia of up to 7 log~10~ c/mL. The majority of these subjects had an inducible viral reservoir, indicating that they were infected with replication-competent viruses \[[@OFV144C2], [@OFV144C3]\]. We confirmed that our patient\'s CD4^+^ T cells were susceptible to superinfection with R5- and X4-tropic viruses, with similar frequencies of infected cells to those we have observed following in vitro infection of healthy donor PBMCs \[[@OFV144C11]\]. Furthermore, we were able to detect outgrowth of endogenous HIV-1 in CD4^+^ T cells after in vitro activation, albeit at a low level, indicating a persistent inducible reservoir. Although posttreatment controllers thus show some virological similarities with patients with spontaneous elite control of HIV-1, an intriguing difference is the lower activation status in the former \[[@OFV144C12]\]. Our patient also showed posttreatment control of immune activation: the frequency of CD38^+^ CD8^+^ T cells has remained within normal limits throughout follow up.

With regard to HIV-specific immune responses, this case is distinct from previously described posttreatment controllers \[[@OFV144C2], [@OFV144C3]\]. CD8^+^ T-cell inhibition of both heterologous and autologous HIV-1 replication was detected at a low CD8^+^/CD4^+^ cell ratio. Although these responses were less potent than was observed in HIV controllers (median 85%, n = 20) \[[@OFV144C8], [@OFV144C13]\], they nevertheless surpassed that of chronic ART-treated individuals who were virologically suppressed for ≥1 year (median 24%, n = 42; our unpublished observations). This result suggests that our patient\'s CD8^+^ T-cell antiviral responses were likely to be a contributing factor to her virological control, rather than a consequence of it. The preserved and broad HIV-1-specific CD4^+^ T-cell responses observed in this patient are also particularly surprising when taking into account the profound CD4^+^ T-cell depletion observed before ART initiation. It is noteworthy that this patient had detectable CD4^+^ T cell responses (polyfunctional and proliferative) in 2004 and 2008 ([Supplementary Figures 2--4](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1)). Furthermore, we were able to show that CD4^+^ T cells were targeted to multiple regions of vulnerability within Gag. Such responses have been associated with spontaneous control of viremia \[[@OFV144C9], [@OFV144C14]\]. It is not known whether this association is mediated by direct cytolytic mechanisms or indirectly, through provision of effective help to CD8^+^ T cells. This deserves further exploration. We also considered the possibility that humoral responses contributed to this patient\'s posttreatment control, because broadly neutralizing antibodies may play a role in controlling viremia in rare cases \[[@OFV144C15]\]. However, we found only low levels of neutralizing antibodies to heterologous virus in this case, when tested during the early period of aviremia in 2006--2007 (data not shown).

CONCLUSIONS {#s5}
===========

In conclusion, we have identified an atypical case of posttreatment control, which may have been achieved through very early ART during PHI combined with effective cell-mediated immune responses. Our data suggest that strategies aiming to induce such immune responses during early ART might influence posttreatment virological control.

Supplementary Material {#s6}
======================

[Supplementary material](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv144/-/DC1) is available online at Open Forum Infectious Diseases (<http://OpenForumInfectiousDiseases.oxfordjournals.org/>).
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